Congress trades
Sarepta Therapeutics, Inc. (SRPT)
About Sarepta Therapeutics, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Michael E. Severino
- Employees
- 835
- Listed since
- Jun 4, 1997
- Market value
- $2.3B
- Price to earnings
- -
- Earnings per share
- -$1.30
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 4, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 5, 2026 | -$0.05 | $0.22 | $401.3M | $366.4M | EPS missRevenue beat |
| Q1 FY2026reported May 6, 2026 | $3.16 | $0.98 | $730.8M | $474.2M | EPS beatRevenue beat |
| Q4 FY2025reported Feb 25, 2026 | -$3.58 | -$1.03 | $442.9M | $369.6M | EPS missRevenue beat |
| Q3 FY2025reported Nov 3, 2025 | -$1.80 | -$0.73 | $399.4M | $335.8M | EPS missRevenue beat |
| Q2 FY2025reported Aug 6, 2025 | $2.02 | $0.83 | $611.1M | $530.7M | EPS beatRevenue beat |
| Q1 FY2025reported May 6, 2025 | -$4.60 | -$0.87 | $744.9M | $687.5M | EPS missRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 24, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Douglas S. IngramChief Executive Officer | $1.2M | $6.0M | $669K | $7.8M |
| Louise Rodino-Klapac, Ph.D.President, Research and Development and Technical Oper | $753K | $2.6M | $1.1M | $4.5M |
| Ian M. EstepanPresident, Chief Operating Officer | $741K | $2.6M | $1.1M | $4.4M |
| Ryan H. WongExecutive Vice President, Chief Financial Officer | $480K | $2.2M | $553K | $3.2M |
The summary compensation table from the 2025 proxy statement, current executives only. 2 executives who have since left the company are named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $341.3M | 18,994,958 | +28.7% | 18.02% |
| State Street Corp | $160.2M | 8,916,090 | +34.8% | 8.46% |
| Vanguard Portfolio Management LLC | $150.5M | 8,377,470 | +26.2% | 7.95% |
| Two Sigma Investments, LP | $82.6M | 4,598,735 | +0.1% | 4.36% |
| Vanguard Capital Management LLC | $82.5M | 4,591,755 | +0.3% | 4.36% |
| First Trust Advisors LP | $78.5M | 4,365,951 | +5.6% | 4.14% |
| AQR Capital Management LLC | $76.9M | 4,325,689 | -32.8% | 4.10% |
| Geode Capital Management, LLC | $49.8M | 2,771,758 | +39.4% | 2.63% |
| Erste Asset Management Gmbh | $45.5M | 2,568,945 | -13.5% | 2.44% |
| Marshall Wace, LLP | $39.6M | 2,206,022 | +204.3% | 2.09% |
| Morgan Stanley | $39.6M | 2,202,641 | -15.2% | 2.09% |
| Abrdn PLC | $39.4M | 2,194,948 | -5.3% | 2.08% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in SRPT
17 disclosures of 17 on record · median 35d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | -59.7%S&P +41.5% · vs S&P 500 -101.1% | Apr 14, 2025 | May 6, 2025 | 22d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -79.6%S&P +69.8% · vs S&P 500 -149.4% | Jul 14, 2023 | Aug 21, 2023 | 38d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -83.0%S&P +74.7% · vs S&P 500 -157.7% | Jun 13, 2023 | Jul 11, 2023 | 28d |
| Daniel S. Goldman | Stock | Sale | $15,001 - $50,000 | -84.3%S&P +86.2% · vs S&P 500 -170.5% | Apr 10, 2023 | May 19, 2023 | 39d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -85.9%S&P +88.5% · vs S&P 500 -174.4% | Mar 6, 2023 | Apr 20, 2023 | 45d |
| Daniel S. Goldman | Stock | Purchase | $15,001 - $50,000 | -85.9%S&P +88.5% · vs S&P 500 -174.4% | Mar 6, 2023 | Apr 17, 2023 | 42d |
| Daniel S. Goldman | Stock | Sale | $1,001 - $15,000 | -82.4%S&P +87.7% · vs S&P 500 -170.1% | Jan 31, 2023 | Feb 24, 2023 | 24d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -82.5%S&P +117.8% · vs S&P 500 -200.3% | Nov 6, 2020 | Dec 9, 2020 | 33d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -84.1%S&P +125.4% · vs S&P 500 -209.5% | Sep 14, 2020 | Oct 14, 2020 | 30d |
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | -86.2%S&P +139.0% · vs S&P 500 -225.2% | Jun 10, 2020 | Jul 17, 2020 | 37d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -83.3%S&P +140.5% · vs S&P 500 -223.8% | Dec 13, 2019 | Jan 6, 2020 | 24d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -73.5%S&P +160.2% · vs S&P 500 -233.8% | Oct 10, 2019 | Nov 15, 2019 | 36d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -73.6%S&P +157.6% · vs S&P 500 -231.2% | Oct 11, 2019 | Nov 15, 2019 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -82.2%S&P +165.7% · vs S&P 500 -247.9% | Apr 9, 2019 | May 14, 2019 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -83.6%S&P +173.8% · vs S&P 500 -257.4% | Mar 11, 2019 | Apr 16, 2019 | 36d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -84.3%S&P +172.9% · vs S&P 500 -257.2% | Feb 26, 2019 | Mar 8, 2019 | 10d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -85.5%S&P +173.1% · vs S&P 500 -258.5% | Feb 27, 2019 | Mar 8, 2019 | 9d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded SRPT?
Gilbert Ray Cisneros, Jr., Josh Gottheimer, Daniel S. Goldman disclosed SRPT transactions in the filings shown here.
How quickly are SRPT trades disclosed?
Congressional disclosures took a median of 35 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.